Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | HTT | P42858 | 8/20 | 0.50 |
| ▸ | MITF | O75030 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2033648 | 0.85 | GPR35 (0.39) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL4874040 | 0.85 | MAPT (0.58) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL788257 | 0.76 | HTT (0.54) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL17347507 | 0.76 | MAPT (0.54) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL23634773 | 0.76 | MAPT (0.50) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL12832961 | 0.76 | MAPT (0.60) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL8757036 | 0.73 | MAPT (0.38) | MAPTHTTMITFLMNASMN1; SMN2 | |
| SCHEMBL10968449 | 0.72 | MAPT (0.61) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL10961504 | 0.71 | PRMT1 (0.61) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL8565505 | 0.71 | MAPT (0.45) | MAPTHTTMITFKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449570-B2 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7291603-B2 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1572709-A3 | USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES | PTC Therapeutics, Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1572709-A2 | USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES | PTC Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1534726-A2 | NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS | PTC Therapeutics, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004009610-A2 | USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009609-A2 | NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | NSUN2, UPF1, NSUN3 | MAPT 3685/4885HTT 68/4885MITF 224/4885 |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | MAPT 2321/4885HTT 174/4885MITF 587/4885 |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | MAPT 2321/4885HTT 174/4885MITF 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.